The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: YM Biosciences

Monday Deal Review: February 18, 2013

Welcome to your Monday Biotech Deal Review for February 18, 2013! This week saw Gilead finally close its acquisition of YM Biosciences, with YM’s shares now de-listed from trading on the NYSE Amex and the TSX. Shareholders were given $2.65 for each of their common shares during the plan of arrangement.  On the investment front, Innovotech, RepliCel, Lignol, Biosenta and Biosign each had announcements relating to the close or amendment of existing private placements.  Click on to see the full details.

Read more of this post

Monday Deal Review: February 11, 2013

Welcome to your Monday Biotech Deal Review for February 11, 2013! This week saw YM Biosciences obtain the required court approval necessary before their plan of arrangement acquisition by Gilead could proceed. The transaction is essentially free to proceed by the effective date of the agreement. Cangene has acquired a hemophilia compound from the remaining assets of Inspiration Biopharmaceuticals, which is undergoing bankruptcy proceedings. Cangene paid $5.9 million for the compound. Also in the news, Stem Cell Therepuetics will undergo a plan of arrangement with Trillium Therepeutics, where the two companies will effectively be merged and continue to operate under Stem Cell’s name.

Of course, there was considerably more activity this week, so click through to get the full story!

Read more of this post

Monday Deal Review: February 4, 2013

Welcome to your Monday Biotech Deal Review for February 4, 2013! This week saw significant activity in the sector generally  On the M&A side, Valeant continued their ongoing acquisition strategy, buying the Russian Natur Product International, a primarily OTC private pharma company. Gilead’s acquisition of YM Biosciences took one step closer to completion as YM shareholders approved the statorily mandated vote to approve the plan of arrangement that will facilitate the arrangement. Court approval is now required as one of the final steps. Microbix was also involved in the week’s M&A activity, having sold its water for injections business to Irvine Scientific. The there was also significant investment activity this week, including Biosenta announcing a new private placement.

See detail on these and the the rest of the week’s major biotech stories by clicking through!

Read more of this post

Monday Deal Review: January 21, 2013

Welcome to your Monday Biotech Deal Review for January 21, 2013!  Medicago made news last week with a $15 million loan agreement with an unnamed pharmaceutical company. The funds are being used for Medicago’s plant-based VLP vaccine pipeline. As the agreement provides for potential licensing options with that partner, we will be watching closely to see any further announcements.

YM Biosciences, as it continues with its plan of arrangement transaction with Gilead, has received the endorsement of two proxy firms who have recommended to shareholders that they vote in favour of the transaction. This will likely allow YM Biosciences to obtain the shareholder approval required by statute to be able to continue with the arrangement.

Paladin labs, meanwhile, has closed their acquisition of a controlling stake in Ativa Pharma of Mexicom, and has also in-licensed a new biologic from Apeiron Biologics. Also, last week we saw Theratechnologies conclude their recent issues with the NASDAQ exchange by voluntarily delisting. They remain on the TSX, however.

As always, click through to see more on these deals as well as the rest of last week’s major biotech activity.

Read more of this post

Monday Deal Review: December 17, 2012

Welcome to your Monday Biotech Deal Review for December 17, 2012.  This week saw the completion of a number of previously announced acquisitions, as well as the announcement of new ones. The latter group includes Gilead’s acquisition of YM Biosciences and Helix’s sale of Rivex to Pharmascience. See the details on these major transactions, as well as the past week’s other biotech news, by clicking through.

Read more of this post

Monday Deal Review: December 10, 2012

Welcome to your Monday Biotech Deal Review for December 10, 2012.  This week saw significant activity in the commercial and licensing agreements arena, as well as a couple M&Eh transactions. Of particular note is Valeant’s commercial resolution of their ongoing issues with Gladerma SA stemming from Valeant’s recent purchase of Medicis.  On the M&A side of things, Biosign has purchased their exclusive distributor Bioanalytics Inc. hot on the heels of closing their recent private placement, which closed the previous week. See the rest of a relatively busy past week’s major biotech deals by clicking through!
Read more of this post

Monday Biotech Deal Review: March 12, 2012

Welcome to your Monday Biotech Deal Review for Monday March 12, 2012.  Following a break, the Monday Biotech Deal Review is back with summaries of biotech transactions over the previous weeks.  Activity has been impressive over the past month, with pharma-giant Valeant Pharmaceuticals syndicating $600M in senior secured indebtedness under its existing senior credit facility to fund (among other things) future acquisitions, Alexion Pharmaceuticals completing its acquisition of Enobia Pharma for $610M and Futuremed Healthcare Products Corporation was acquired by Cardinal Health Inc.  Also of note was the recent $80.5M equity financing by YM BioSciences as well as the reverse takeover of The Atman Co. by Biotonix.  Read on to learn more.   Read more of this post

Monday Biotech Deal Review: July 25, 2011

Welcome to your Monday Biotech Deal Review for July 25, 2011.  Interesting tidbits from last week included the termination of the letter of intent relating to the proposed reverse-takeover transaction between Bradmer Pharmaceuticals and P1 Energy Corp., a distribution and marketing agreement between Valeant and Sanofi-aventis Canada, a $15M loan agreement between Protox Therapeutics and Oxford Finance LLC, the filing of a preliminary short-form base shelf prospectus in the Canada and U.S. by YM BioSciences, the closing of a $7M financing round for gIcare Pharma Inc., and the acquisition by Paladin Labs of a significant number of common shares of Afexa Life Sciences.  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: June 6, 2011

Welcome to your Monday Biotech Deal Review for June 6, 2011.  This week’s deal review is brought to you by Norton Rose OR LLP summer student Steven Zuccarelli who, before entering law school at Osgoode Hall Law School, obtained his B.Sc and M.Sc at McMaster University in Biochemistry and Health Sciences, respectively, where he was involved in researching peptide vaccine models.  Steven will be assisting over the summer months with the Monday Deal Review, and it’s great to have him aboard. 

Aside from some interesting commercial deals, as well as CardioComm’s related-party announcement of a $788k asset purchase, things were fairly slow last week.  Read on to learn more. 

Read more of this post

Monday Biotech “Happy Holidays” Deal Review: December 27, 2010

Welcome to your Monday Biotech “Happy Holidays” Deal Review!  For those who may have noticed, last week the Monday Biotech Deal Review took its own holiday, so this week’s digest contains biotech news spanning the past two weeks – to ensure you don’t miss a single drummer boy’s beat.  It has been a busy two weeks, with a notable $40M public offering by YM BioSciences of common shares that was announced, priced and closed, as well as an update by Angiotech with respect to its debt restructuring efforts.  There have also been some interesting strategic partnerships and licensing activity over the break.  Read on to learn more.     Read more of this post

Monday Biotech Deal Review: October 18, 2010

Despite the short week, it was a busy one in the Canadian biotech sector. Read on to learn about the Labopharm / Paladin licensing deal, Ondine’s new facelift (and 15:1 equity liposuction), and various other biotech updates and news. 

Read more of this post

Monday Biotech Deal Review: October 4, 2010

This week’s Monday Deal Review brings you the usual assortment of biotech wheelings and dealings from the past week, including a summary of the newly completed Valeant / Biovail merger.  Read more of this post

Monday Biotech Deal Review: August 16, 2010

Another decent week for Canada’s biotech companies, with about $30 million of securities sold and more deals launched. Big headlines this week for Alectos’ Alzheimer’s collaboration with Merck, which gets a US$289 million number but declines to split out the up-front payment or other details of the fee structure. Also, eHealth Ontario is spending significant money again, this time awarding a $46.5 million contract to a CGI subsidiary for work on a chronic disease management system. Finally, Biovail sold some CRO assets in a deal that passed under the radar until their Q2 report. 

And, to make sure an important thank-you doesn’t fly under the radar, I’d like to include an above-the-fold thanks this week to Keldeagh Lindsay, the Ogilvy Renault student who has been doing a great job helping out with the Monday Biotech Deal Review all summer. And now,

Read more of this post

Monday Biotech Deal Review: June 7, 2010

This week saw a resurgence of deal activity on the Canadian landscape. Lots of good news here, including Resverlogix’s [$9.2m] haul and a $30m exit for Montreal’s Resonant Medical.  Not all was sunny though: Cynapsus downsized its unit price and Amorfix just downsized, while the Bankruptcy and Insolvency Act got its own workout (har) this week. Read more of this post

Monday Biotech Deal Review: May 3, 2010

I guess the excitement of BIO was driving deals this week. To the delight of the economic development folks, government was in on the action — Ontario announced a BIP investment and announced a whole new strategy, and OICR funded three equity deals. The private sector was also out in force, with four new licensing deals (including some interesting structures) and more securities than the week might otherwise … warrant. Keep reading after the jump…

Monday Biotech Deal Review: March 22, 2010

Bought deals are all the rage this week, with BioExx and Osta Biotechnologies both heading in that direction.  Also, everywhere we look, warrants are being exercised and debentures are being converted. We even noted the green shoots of a new Canadian listed biotech company poking through the ground via a CPC transaction.  Is there a Spring thaw in Canada’s biotech capital markets?  Read more of this post

Monday Biotech Deal Review: March 8, 2010

A busy week in Canadian deals, with Paladin Labs in a global transaction with SpePharm; M&A activity from therapeutics and consulting companies; the last of the SIFT/SR&ED deals; over $20 million of new offerings from BioSign, Bradmer and YM; government funding for Medicago and Isotechnika; a new standby equity deal from Yorkville for Allon; and the closing of the first deal of the rest of BioMS’ new life. Read more of this post

Monday Biotech Deal Review: February 15, 2010

A busy Monday Deal Review is headlined by Labopharm and ProMetric on the securities front, MDS’ final divestiture on the M&Eh front and Biovail and Bioniche on the licensing front, and there’s lots more activity behind those for over $100 million of deals.  Check out all the details (and the witty headlines) after the jump…

Monday Biotech Deal Review: January 18, 2010

Another strong week for Canadian deals. Light on securities, but heavy on M&A, licensing and partnerships.  MedGenesis and Cyplasin brought assets in, Canada and Australia are doing a do-sa-do (Topigen-Pharmaxis, YM-Cytopia), and Trillium Therapeutics signed an out-license to Biogen, while Medicure is shopping its lead program around.  Less good news for Haemacure and Forbes Medi-Tech, but plenty of other deal info, including 7 HTX investments, to be found Read more of this post

Monday Biotech Deal Review: December 21, 2009

This week’s deal review shows no signs of a holiday showdown.  In Canada, BioMS’ deal with Spectral Diagnostics was interesting as a possible indicator of more to come and internationally, 5 new pharma deals were announced this morning including a $430 million deal that OncoGenex landed from Teva joining new links between Athersys and Pfizer, Lilly and Incyte, sanofi-aventis and Chattem and Seattle Genetics and GSK.  Check out the past week’s Canadian deal-making (and breaking) after the jump…

Monday Biotech Deal Review: December 14, 2009

In this week’s biotech deal review, some stimulus money finds its way to biotech, some M&A finds its way to shareholders’ votes, the NRC-BRI finds its way to two deals, and Patheon finds itself entering a new fiscal year a bit less burdened.  Even some securities may find their way into the market…

Read more of this post

Monday Deal Review: July 6, 2009

B&W_BigNickelLearn more about Neuromed’s deal with CombinatoRx, check out what MedMira’s been doing with all the cash from its equity line, and find out who’s closed deals and who’s just closing doors in this week’s Monday Deal Review after the jump…

Monday Deal Review: March 30, 2009

Monday Deal Review: March 23, 2009

A relativley light week for Canadian deal and company info this week, but we have all the news that’s fit to print (if not necessarily fit to distribute in the U.S.) after the jump…

Follow

Get every new post delivered to your Inbox.

Join 131 other followers